Determination of irinotecan, SN‐38 and SN‐38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. Issue 1 (10th April 2017)

• Record Type: Journal Article
• Authors: Atasilp, Chalirmporn; Chansriwong, Pichai; Sirachainan, Ekapob; Reungwetwattana, Thanyanan; Puangpetch, Apichaya; Prommas, Santirhat; Sirilerttrakul, Suwannee; Rerkarmnuaychoke, Budsaba; Wongwaisayawan, Sansanee; Sukasem, Chonlaphat
• Is Part Of: Journal of clinical laboratory analysis. Volume 32:Issue 1(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-04-10
• Subjects: colorectal cancer -- CPT‐11 -- LC‐MS/MS -- SN‐38 -- SN‐38G; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.22217
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract : Background: Irinotecan (CPT‐11) is chemotherapy used mainly in the metastatic colorectal cancer. The purpose of this study was to develop and validate the LC‐MS/MS for the simultaneous determination of CPT‐11, SN‐38, and SN‐38G. Methods: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5‐10 000 ng/mL for CPT‐11, 5‐1000 ng/mL for SN‐38, and 8‐1000 ng/mL for SN‐38G. Results: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT‐11, ≤8.70% and 8.31% for SN‐38, and ≤9.90 and 9.64% for SN‐38G. Conclusion: This method was successfully used to quantify CPT‐11, SN‐38, and SN‐38G and applied to a pharmacokinetic study.